Johnson & Johnson Must Pay Louisiana $257.7 Million Over Risperdal Marketing Practices

Bloomberg -- Johnson & Johnson lost a $257.7 million jury verdict in Louisiana for making misleading claims about the safety of the company’s Risperdal antipsychotic drug.

MORE ON THIS TOPIC